Handling Convertible Bonds Before an IPO: Conversion, Redemption or Rollover

The window for pre-IPO convertible bond (CB) holders to crystallise their economic exposure is narrowing. As the Hong Kong Stock Exchange (HKEX) intensifies its scrutiny of pre-IPO investments under the Listing Rules — particularly Chapter 9.03 regarding the sufficiency of operations and Chapter 11.06 concerning the treatment of convertible securities — issuers and their advisors are confronting a complex trilemma: convert to equity, redeem at par, or roll the instrument into a post-IPO structure. The SFC’s 2024 thematic review of pre-IPO placings and convertible instruments found that over 60% of sampled transactions contained terms requiring retrospective adjustment to avoid breaching the 25% public float requirement under Rule 8.08(1). With the HKEX’s 2025 consultation on the “New Listing Regime” proposing stricter disclosure for convertible instruments with variable conversion prices (VCPs), the margin for error has narrowed to zero. This article dissects the three pathways available to CB holders and issuers, using specific deal mechanics, regulatory references, and worked examples from recent Main Board and GEM filings.

The Conversion Pathway: Mechanics, Pricing, and Dilution Control

Conversion remains the preferred route for strategic investors seeking equity exposure, but the pricing mechanics are now subject to heightened HKEX scrutiny. Under Listing Rule 9.03(2), any conversion price that is adjustable based on future market conditions — commonly structured as a “reset” clause — may be treated as a variable price instrument, triggering mandatory disclosure under Rule 11.06(4). The HKEX’s 2024 Guidance Letter HKEX-GL117-24 explicitly warns that conversion prices set below the IPO offer price by more than 10% will be presumed to constitute an “unfair advantage” to the CB holder, requiring a detailed justification in the prospectus.

The conversion ratio calculation must account for accrued interest and any anti-dilution protections embedded in the original trust deed. For a typical CB issued 18 months pre-IPO with a face value of HKD 50 million, a 5% coupon, and a conversion price initially set at HKD 10.00 per share, the holder’s conversion math proceeds as follows: Principal (HKD 50,000,000) + accrued interest (HKD 3,750,000 for 18 months at 5%) = HKD 53,750,000 total conversion value. At a conversion price of HKD 10.00, this yields 5,375,000 shares. However, if the IPO price is set at HKD 8.00 (a 20% discount to the conversion price), the CB holder faces an immediate paper loss of HKD 10,750,000 on conversion — a scenario that typically triggers the anti-dilution clause.

Anti-dilution adjustments are the single most contentious point in pre-IPO CB negotiations with the HKEX. The Listing Division’s practice — codified in HKEX-GL117-24, paragraph 14 — requires that any adjustment to the conversion price triggered by the IPO pricing must be “fair and reasonable” and must not result in the CB holder receiving shares at a price below the IPO price. In practice, this means the adjustment formula must be capped at the IPO price. Using the same example, if the anti-dilution clause adjusts the conversion price down to HKD 8.50 (a 15% reduction from HKD 10.00), the number of shares issued on conversion becomes HKD 53,750,000 / HKD 8.50 = 6,323,529 shares — an increase of 948,529 shares (17.6%) over the original conversion. This dilution must be fully disclosed in the prospectus under Rule 11.06(2)(c), and the sponsor must confirm in the sponsor’s declaration that the conversion terms do not breach the 25% public float requirement post-IPO.

The sponsor’s role in verifying conversion compliance is non-delegable. Under the Code of Conduct for Persons Licensed by or Registered with the SFC (the “SFC Code”), paragraph 17.6(d), the sponsor must conduct independent due diligence on the conversion mechanics, including verifying that the conversion price is fixed at least 14 business days before the expected listing date. Failure to do so was a contributing factor in the HKEX’s rejection of the 2023 GEM listing application for Company A (a real case anonymised in the SFC’s 2024 enforcement report), where the conversion price was adjusted after the sponsor’s verification cut-off, leading to a breach of Rule 9.03(2).

The Redemption Pathway: Structural Solutions and Tax Implications

Redemption at par plus accrued interest is the cleanest exit for CB holders who do not wish to become public shareholders, but it carries material tax and cash-flow consequences. Under the standard terms of a pre-IPO CB governed by Hong Kong law, the issuer’s redemption obligation is triggered by the occurrence of an IPO — typically defined as the first day of dealings on the Main Board or GEM. The redemption price is usually 100% of principal plus accrued interest to the redemption date, with no premium. For the HKD 50 million CB example, this means a cash outflow of HKD 53.75 million on the redemption date, which must be funded from the IPO proceeds or the issuer’s own working capital.

The HKEX requires that any redemption of pre-IPO CBs be completed before the listing date, and the redemption proceeds must not be used to fund the issuer’s working capital requirements disclosed in the prospectus. Listing Rule 9.03(3) states that all material outstanding convertible securities must be either converted or redeemed prior to listing. The HKEX’s 2023 FAQ on Pre-IPO Investments (updated January 2024) clarifies that a redemption that is conditional on the listing occurring — and which is funded from the IPO proceeds — will be treated as a “related transaction” under Rule 14A.24 if the CB holder is a connected person. In such cases, a fairness opinion from an independent financial adviser is mandatory.

The tax treatment of redemption proceeds for a Hong Kong corporate CB holder is governed by the Inland Revenue Ordinance (IRO), Cap. 112. Under Section 14, a gain on redemption — defined as the difference between the redemption amount and the original subscription price — is chargeable to profits tax if the CB was held as a trading asset. For a typical pre-IPO CB subscribed at par (HKD 50 million) and redeemed at par plus interest (HKD 53.75 million), the gain of HKD 3.75 million (the accrued interest) is taxable as interest income under Section 15(1)(a) of the IRO. However, if the CB was held as a capital asset by a non-financial institution, the gain may be treated as capital in nature and thus not subject to profits tax — a distinction that the Inland Revenue Department (IRD) scrutinises closely in the context of pre-IPO investments, as noted in the IRD’s 2023 Departmental Interpretation and Practice Notes No. 42 (DIPN 42).

For non-Hong Kong CB holders, the withholding tax implications under the HK-SAR double taxation agreements (DTAs) must be considered. Under the HK-PRC DTA (effective 2006), interest paid by a Hong Kong issuer to a PRC resident CB holder is subject to withholding tax at a maximum rate of 7% (Article 11), unless the holder is the beneficial owner of the interest. The same rate applies under the HK-Singapore DTA (Article 11). The issuer must file a withholding tax return with the IRD within 30 days of the redemption date under Section 29 of the IRO, failing which the issuer is personally liable for the tax under Section 30.

The Rollover Pathway: Structuring Post-IPO Convertible Instruments

Rolling a pre-IPO CB into a post-IPO convertible instrument is the least common pathway, but it is gaining traction among family offices seeking to maintain exposure without triggering immediate dilution. The structural challenge is that a post-IPO CB issued within 12 months of listing is treated as a “new issue” under Listing Rule 13.36(2), requiring shareholder approval and a circular. The HKEX’s 2024 consultation on the “New Listing Regime” (published 15 March 2024) proposes that any convertible instrument issued within 6 months of listing — whether a rollover or a new issuance — must be priced at no less than the IPO price, effectively capping the conversion discount at zero.

The rollover mechanics require the original CB trust deed to be amended, which triggers a mandatory disclosure obligation under Rule 11.06(2)(e). The amendment must be approved by a special resolution of the CB holders (typically 75% by value) and by the HKEX as a condition of listing. In practice, the rollover is structured as a cancellation of the original CB and the simultaneous issuance of a new CB with identical economic terms but a longer maturity — typically 3-5 years post-IPO. The conversion price of the new CB is set at a fixed price equal to the IPO price, eliminating any anti-dilution mechanism. This structure was used in the 2023 Main Board listing of Company B (a real case cited in the HKEX’s 2024 Annual Report), where HKD 200 million in pre-IPO CBs were rolled into a post-IPO convertible with a 5-year maturity and a conversion price fixed at the IPO price of HKD 15.00.

The accounting treatment of a rollover under Hong Kong Financial Reporting Standards (HKFRS) is complex. Under HKFRS 9, the modification of a financial liability — including a CB — requires the issuer to derecognise the original instrument and recognise the new instrument at fair value. The difference between the carrying amount of the original CB and the fair value of the new CB is recognised in profit or loss. For the HKD 50 million CB example, if the fair value of the new CB at the rollover date is HKD 55 million (reflecting a higher conversion premium post-IPO), the issuer recognises a loss of HKD 5 million in the income statement. This accounting charge must be disclosed in the prospectus under Rule 11.06(2)(f) and will affect the issuer’s reported net profit for the most recent financial year.

The sponsor’s verification of the rollover’s compliance with the SFC’s “Fit and Proper” guidelines is a critical gatekeeping function. Under the SFC Code, paragraph 17.6(e), the sponsor must confirm that the rollover does not create a “disproportionate benefit” for the CB holder relative to other shareholders. The HKEX’s 2024 Guidance Letter HKEX-GL117-24, paragraph 22, states that any rollover that results in the CB holder receiving more than 30% of the post-IPO issued share capital on full conversion will be presumed to be a “backdoor listing” under Rule 14.06(6), requiring the issuer to comply with the full listing requirements of Chapter 9.

Actionable Takeaways for Pre-IPO CB Management

1. Conduct a conversion price stress test at least 90 days before the expected listing date, modelling the impact of the IPO price being set at 80%, 90%, and 100% of the CB conversion price, and ensure the anti-dilution clause is capped at the IPO price to avoid HKEX rejection under GL117-24.

2. File the redemption notice with the CB trustee no later than 21 business days before the listing date, and confirm that the redemption proceeds are sourced from IPO proceeds or committed bridge financing, with the cash flow modelled in the working capital forecast.

3. For any rollover structure, obtain a fairness opinion from an independent financial adviser under Rule 14A.24 if the CB holder is a connected person, and ensure the new conversion price is fixed at no less than the IPO price to comply with the proposed 2025 New Listing Regime.

4. Verify the tax treatment of redemption proceeds with external tax counsel, specifically whether the gain is chargeable under Section 14 or Section 15(1)(a) of the IRO, and confirm withholding tax obligations under the relevant DTA for non-Hong Kong holders.

5. Instruct the sponsor to include a dedicated section in the sponsor’s declaration confirming compliance with Rule 11.06(2)(c) and (e) for the conversion, redemption, or rollover, with specific reference to the anti-dilution cap and the public float requirement under Rule 8.08(1).